Management of inflammaging in kidney diseases: focusing on the current investigational drugs

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18383

Full metadata record

DC Field	Value	Language
dc.contributor.author	Gaikwad, Anil Bhanudas	-
dc.date.accessioned	2025-03-17T04:39:21Z	-
dc.date.available	2025-03-17T04:39:21Z	-
dc.date.issued	2024-10	-
dc.identifier.uri	https://www.tandfonline.com/doi/full/10.1080/13543784.2024.2417755	-
dc.identifier.uri	http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18383	-
dc.description.abstract	To improve kidney disease treatments, it is crucial to understand how inflammaging affects patients´ longevity. We could potentially slow down kidney disease progression and enhance longevity by targeting specific pathways involved in inflammaging with potential drugs.	en_US
dc.language.iso	en	en_US
dc.publisher	Taylor & Francis	en_US
dc.subject	Pharmacy	en_US
dc.subject	Autophagy	en_US
dc.subject	Caloric restriction	en_US
dc.subject	Inflammaging	en_US
dc.subject	Kidney diseases	en_US
dc.subject	Metabolic dysregulation	en_US
dc.title	Management of inflammaging in kidney diseases: focusing on the current investigational drugs	en_US
dc.type	Article	en_US
Appears in Collections:	Department of Pharmacy

Files in This Item:

There are no files associated with this item.